Thus MDM2 and CDK4 immunostaining are helpful adjuncts to differentiate WDLPS from benign adipose tumors and discriminate DDLPS from poorly differentiated sarcomas [8], but others molecular factors differentially expressed in LPS subgroups could represent an helpful tool to identify subtypes and predict disease outcome. The gene discussed is MDM2; the disease is sarcoma.